Brexit: Life Science Firms In An ‘Impossible Position’
Guidance Still Awaited On Licensing & Pharmacovigilance
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
